Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2607-2617

  Li, Keyu ^a   Tavaré, Richard ^a   Zettlitz, Kirstin A ^a   Mumenthaler, Shannon M ^b   Mallick, Parag ^b,c   Zhou, Yu ^d   Marks, James D ^d   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; GEFITINIB; SCATTER FACTOR RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ZIRCONIUM; IMMUNOGLOBULIN FRAGMENT; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER RESISTANCE; CELL CLONING; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; IMAGE QUALITY; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; HUMAN; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY; SCID MOUSE; SCINTISCANNING; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LUNG NEOPLASMS; MICE; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-MET; RADIOISOTOPES; RADIOPHARMACEUTICALS; ZIRCONIUM;

EID: 84919360932     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0363     Document Type: Article

References (35)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility, and more. Nat Rev Mol Cell Biol 2003;4:915-25.
2. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45.
3. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
4. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefi tinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
5. Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, et al. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-12.
6. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011;11:1655-62.
7. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 2012;30:3884-92.
8. Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008;35:1857-67.
9. Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, et al. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med 2012;53:1592-600.
10. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-93.
11. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 2009;50:2-5.
12. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
13. Li L, Olafsen T, Anderson AL, Wu A, Raubitschek AA, Shively JE. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug Chem 2002;13:985-95.
14. Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM. Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. Bioconjug Chem 2008;19:2527-34.
15. Barat B, Sirk SJ, McCabe KE, Li J, Lepin EJ, Remenyi R, et al. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjug Chem 2009;20:1474-81.
16. McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol 2012;14:336-47.
17. Olafsen T, Sirk SJ, Olma S, Shen CK, Wu AM. ImmunoPET using engineered antibody fragments: fl uorine-18 labeled diabodies for same-day imaging. Tumour Biol 2012;33:669-77.
18. Girgis MD, Federman N, Rochefort MM, McCabe KE, Wu AM, Nagy JO, et al. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. J Surg Res 2013;185:45-55.
19. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-55.
20. Marks C, Marks JD. Phage libraries - a new route to clinically useful antibodies. N Engl J Med 1996;335:730-3.
21. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23:1105-16.
22. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9:767-74.
23. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471-8.
24. Fu M, Brewer S, Olafsen T, Wu AM, Gordon LK, Said J, et al. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. Mol Imaging Biol 2013;15:68-78.
25. McCabe KE, Wu AM. Positive progress in immunoPET-not just a coincidence. Cancer Biother Radiopharm 2010;25:253-61.
26. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 2010;25:375-85.
27. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A 1998;95:6157-62.
28. Marks JD, Bradbury A. Selection of human antibodies from phage display libraries. In:Lo BKC, editor. Antibody engineering: methods and protocols. Totowa, NJ: Humana Press; 2004. p. 161.
29. Knowles SM, Zettlitz KA, Tavare R, Rochefort MM, Salazar FB, Stout DB, et al. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med 2014;55:452-9.
30. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010;285:36149-57.
31. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
32. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013;110:E2987-96.
33. Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, et al. Nonagonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PloS ONE 2012;7:e34658.
34. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
35. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.